NCT05495620View on ClinicalTrials.gov

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

UnknownOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

September 30, 2023

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

Carfilzomib

"Intravenous~carfilzomib, lenalidomide, dexamethasone"

DRUG

Lenalidomide

Oral

DRUG

Dexamethasone

Oral or intravenous

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Dong-A University Hospital

OTHER